NasdaqGS - Nasdaq Real Time Price • USD
Denali Therapeutics Inc. (DNLI)
As of 11:29 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 16 | 14 |
| Avg. Estimate | -0.67 | -0.66 | -2.67 | -2.59 |
| Low Estimate | -0.85 | -0.86 | -3.3 | -3.32 |
| High Estimate | -0.43 | -0.39 | -1.42 | -1.18 |
| Year Ago EPS | 1.3 | -0.72 | -1.06 | -2.67 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 12 | 13 | 14 |
| Avg. Estimate | 15.72M | 16.28M | 49.48M | 107.72M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 33.38M | 36.9M | 124M | 367.25M |
| Year Ago Sales | 13.46M | 1.27M | 330.53M | 49.48M |
| Sales Growth (year/est) | 16.80% | 1,184.90% | -85.00% | 117.70% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.68 | -0.8 | -0.8 | -0.7 |
| EPS Actual | 1.3 | -0.72 | -0.86 | -0.68 |
| Difference | 1.98 | 0.08 | -0.06 | 0.02 |
| Surprise % | 291.20% | 10.00% | -7.50% | 2.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.67 | -0.66 | -2.67 | -2.59 |
| 7 Days Ago | -0.67 | -0.67 | -2.69 | -2.63 |
| 30 Days Ago | -0.66 | -0.66 | -2.6 | -2.59 |
| 60 Days Ago | -0.68 | -0.68 | -2.67 | -2.69 |
| 90 Days Ago | -0.54 | -0.75 | -2.91 | -2.46 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 3 | 2 | 4 | 1 |
| Up Last 30 Days | 6 | 6 | 10 | 9 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 3 | 2 | 1 |
Growth Estimates
| CURRENCY IN USD | DNLI | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -151.50% | -- | -- | 8.00% |
| Next Qtr. | 8.30% | -- | -- | 12.40% |
| Current Year | -151.90% | -- | -- | 5.60% |
| Next Year | 3.00% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Wedbush: Outperform to Outperform | 5/8/2024 |
| Maintains | Stifel: Hold to Hold | 5/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/8/2024 |
| Maintains | UBS: Buy to Buy | 4/9/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 2/29/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/28/2024 |
Related Tickers
ALEC Alector, Inc.
5.37
-1.29%
RARE Ultragenyx Pharmaceutical Inc.
41.58
-0.69%
NRIX Nurix Therapeutics, Inc.
16.47
-0.75%
ZLAB Zai Lab Limited
20.64
+6.39%
LEGN Legend Biotech Corporation
46.14
+2.17%
PRTA Prothena Corporation plc
22.30
-0.98%
AKRO Akero Therapeutics, Inc.
19.91
-0.05%
ETNB 89bio, Inc.
8.86
+2.67%
PCVX Vaxcyte, Inc.
74.88
+0.42%
BPMC Blueprint Medicines Corporation
104.95
-0.01%